LivaNova PLC (LIVN)
| Market Cap | 3.35B |
| Revenue (ttm) | 1.39B |
| Net Income (ttm) | -242.47M |
| Shares Out | 54.69M |
| EPS (ttm) | -4.45 |
| PE Ratio | n/a |
| Forward PE | 14.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 865,013 |
| Open | 63.63 |
| Previous Close | 63.41 |
| Day's Range | 60.48 - 63.76 |
| 52-Week Range | 35.00 - 71.92 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 72.43 (+18.18%) |
| Earnings Date | May 6, 2026 |
About LIVN
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing sy... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for LIVN stock is "Buy." The 12-month stock price target is $72.43, which is an increase of 18.18% from the latest price.
News
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article...
LivaNova to Announce First-Quarter 2026 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, ...
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approva...
LivaNova Earnings Call Transcript: Q4 2025
Delivered double-digit revenue and EPS growth in 2025, driven by strong cardiopulmonary and epilepsy performance, expanded margins, and robust cash flow. 2026 guidance calls for 6%-7% revenue growth, continued innovation, and disciplined capital allocation.
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and issued full-year 2026 gui...
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results o...
LivaNova Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is executing a two-phase growth strategy, leveraging core strengths in cardiopulmonary and epilepsy to enter the high-growth OSA market, supported by strong clinical data and recent reimbursement gains. OSA commercialization is staged, with profitability expected by 2029 and significant margin expansion by 2030.
LivaNova to Present at J.P. Morgan Healthcare Conference in January
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference i...
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (A...
LivaNova Transcript: Piper Sandler 37th Annual Healthcare Conference
Management outlined strong 2025 growth, with margin expansion funding OSA market entry and new product launches in CP and oxygenators. Major reimbursement gains in epilepsy will drive volume, while OSA and depression therapy benefit from operational synergies and strategic hiring.
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Ob...
LivaNova to Present at Piper Sandler Healthcare Conference in December
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general...
LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) assi...
LivaNova Transcript: Wolfe Research Healthcare Conference 2025
Leadership is driving a strategic transformation with renewed focus on core innovation, targeting durable growth in epilepsy and cardiopulmonary segments. Entry into the sleep apnea market leverages neuromodulation expertise, with robust financial guidance and investment flexibility through 2028.
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap a...
LivaNova Transcript: Investor Day 2025
A new five-year plan targets high single-digit plus revenue growth, margin expansion, and EPS CAGR in the low double-digits to mid-teens, driven by core cardiopulmonary and epilepsy businesses, and accelerated by OSA entry. OSA is expected to deliver $200M–$400M revenue by 2030, with DTD as a major upside pending CMS approval.
LivaNova Earnings Call Transcript: Q3 2025
Delivered 13% organic revenue growth, margin expansion, and strong cash generation, led by cardiopulmonary and epilepsy segments. Raised 2025 guidance for revenue, EPS, and free cash flow, with major growth expected from ESSENCE in China and ongoing innovation investments.
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-...
LivaNova to Present at Wolfe Research Healthcare Conference in November
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsbur...
LivaNova to Announce Third-Quarter 2025 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2025 results on Wed., Nov. 5,...
LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the International Surgical Sleep Society (ISSS) ...
LivaNova Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Core businesses in neuromodulation and cardiopulmonary are driving strong, sustained growth, with new product launches and market share gains. Expansion into OSA and DTD, supported by clinical data and reimbursement progress, positions the company for long-term growth.
LivaNova Transcript: Baird Global Healthcare Conference 2025
Double-digit growth continues, driven by cardiopulmonary and epilepsy segments, with strong market share gains and strategic pricing. Innovation in heart-lung machines and neuromodulation, plus upcoming reimbursement changes, position the business for further expansion.
LivaNova Appoints Donald Zurbay as a New Director
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company's Board of ...
LivaNova to Host Investor Day on November 12, 2025
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC announced it will host an Investor Day and product showcase on Wed., Nov. 12, 2025.